Krystal Biotech Inc
NASDAQ:KRYS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Krystal Biotech Inc
NASDAQ:KRYS
|
US |
|
C
|
Compass Inc
F:91D
|
US |
|
G
|
Globe Life Inc
DUS:TMJ
|
US |
|
Mitsubishi Corp
F:MBI0
|
JP |
|
M
|
Mastercard Inc
BMV:MA
|
US |
|
D
|
Dongfang Electric Corp Ltd
OTC:DNGFF
|
CN |
|
M
|
Metso Outotec Corp
F:M6Q
|
FI |
|
Galderma Group AG
F:PY30
|
CH |
|
A
|
Ares Capital Corp
XBER:9A2
|
US |
|
O
|
Omnia Holdings Ltd
JSE:OMN
|
ZA |
Wall St Price Targets
KRYS Price Targets Summary
Krystal Biotech Inc
According to Wall Street analysts, the average 1-year price target for KRYS is 344.45 USD with a low forecast of 217.15 USD and a high forecast of 423.15 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is KRYS's stock price target?
Price Target
344.45
USD
According to Wall Street analysts, the average 1-year price target for KRYS is 344.45 USD with a low forecast of 217.15 USD and a high forecast of 423.15 USD.
What is the Revenue forecast for Krystal Biotech Inc?
Projected CAGR
22%
The compound annual growth rate for Revenue over the next 8 years is 22%.
What is the Gross Profit forecast for Krystal Biotech Inc?
Projected CAGR
22%
The compound annual growth rate for Gross Profit over the next 8 years is 22%.
What is the Operating Income forecast for Krystal Biotech Inc?
Projected CAGR
31%
The compound annual growth rate for Operating Income over the next 8 years is 31%.
What is the Pre-Tax Income forecast for Krystal Biotech Inc?
Projected CAGR
44%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 44%.
What is the Net Income forecast for Krystal Biotech Inc?
Projected CAGR
21%
The compound annual growth rate for Net Income over the next 8 years is 21%.
